首页> 美国卫生研究院文献>Oncotarget >Validation study for the hypothesis of internal mammary sentinel lymph node lymphatic drainage in breast cancer
【2h】

Validation study for the hypothesis of internal mammary sentinel lymph node lymphatic drainage in breast cancer

机译:乳腺癌内部前哨淋巴结淋巴引流假说的验证研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

According to axilla sentinel lymph node lymphatic drainage pattern, we hypothesized that internal mammary sentinel lymph node (IM-SLN) receives lymphatic drainage from not only the primary tumor area, but also the entire breast parenchyma. Based on the hypothesis a modified radiotracer injection technique was established and could increase the visualization rate of the IM-SLN significantly. To verify the hypothesis, two kinds of tracers were injected at different sites of breast. The radiotracer was injected with the modified technique, and the fluorescence tracer was injected in the peritumoral intra-parenchyma. The location of IM-SLN was identified by preoperative lymphoscintigraphy and intraoperative gamma probe. Then, internal mammary sentinel lymph node biopsy (IM-SLNB) was performed. The fluorescence status of IM-SLN was identified by the fluorescence imaging system. A total of 216 patients were enrolled from September 2013 to July 2015. The overall visualization rate of IM-SLN was 71.8% (155/216). The success rate of IM-SLNB was 97.3% (145/149). The radiotracer and the fluorescence tracer were identified in the same IM-SLN in 127 cases, the correlation and the agreement is significant (Case-base, rs=0.836, P<0.001; Kappa=0.823, P<0.001). Different tracers injected into the different sites of the intra-parenchyma reached the same IM-SLN, which demonstrates the hypothesis that IM-SLN receives the lymphatic drainage from not only the primary tumor area but also the entire breast parenchyma.
机译:根据腋窝前哨淋巴结的淋巴引流方式,我们假设内部乳腺前哨淋巴结(IM-SLN)不仅从原发性肿瘤区域,而且从整个乳腺实质接受淋巴引流。基于该假设,建立了改进的放射性示踪剂注入技术,该技术可以显着提高IM-SLN的可视化率。为了验证该假设,在乳房的不同部位注射了两种示踪剂。用改良技术注射放射性示踪剂,并在肿瘤周围实质内注射荧光示踪剂。 IM-SLN的位置通过术前淋巴造影和术中伽玛探针确定。然后,进行内部乳腺前哨淋巴结活检(IM-SLNB)。 IM-SLN的荧光状态通过荧光成像系统鉴定。从2013年9月到2015年7月,共有216例患者入选。IM-SLN的总体可视化率为71.8%(155/216)。 IM-SLNB的成功率为97.3%(145/149)。 127例病例在同一IM-SLN中被鉴定出放射性示踪剂和荧光示踪剂,相关性和一致性显着(案例库,rs = 0.836,P <0.001; Kappa = 0.823,P <0.001)。注入到实质内部不同部位的不同示踪剂达到了相同的IM-SLN,这证明了IM-SLN不仅从原发肿瘤区域而且从整个乳房实质获得淋巴引流的假说。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号